Androgenetic Alopecia Clinical Trial
Official title:
Assessment of the Role of the JAK-STAT Pathway in the Pathogenesis of Male Androgenetic Alopecia
It is a well known fact that the JAK-STAT pathway plays a pivotal role in the pathogenesis of alopecia areata. Both phosphorylated STAT 1 and 3 have been found to be upregulated in the disease. However, whether this pathway plays a role in other hair loss disorders remains unclear. The study aims at assessing STAT3 levels in male patients with androgenetic alopecia. The investigators hypothesize that STAT3 levels will be elevated (due to a previous study proving that JAK-STAT pathway is involved in non-immune mediated hair loss in mice.
Background and rationale Androgenetic alopecia occurs in men and women,and is characterised
by the loss of hair from the scalp in a defined pattern. Determining factors appear to be
genetic predisposition coupled with the presence of sufficient circulating androgen.
The transformation of testosterone into dihydrotestosterone(DHT) by type 2 5-alpha reductase,
which causes hair miniaturization,is universally accepted as the main player in the disease's
pathogenesis. Nonetheless,how DHT causes hair thinning is not well understood. New studies
revealed that a lymphocytic microfolliculitis targeting the bulge epithelium along with
deposits of epithelial basement membrane zone immunoreactants are frequent findings in
androgenetic alopecia and could point toward an immunologically driven trigger.
Tyrosine kinases (TKs) are enzymes involved in intracellular signaling that catalyze the
phosphorylation of tyrosine residues on protein substrates. They are key components of
signaling pathways that drive any array of cellular responses including proliferation,
differentiation, migration and survival. Janus kinases (JAKs) are specific TKs.
Signal transducer and activator of transcription (STAT) proteins are transcription
factorsprimarily phosphorylated and activated by JAKs.The JAK-STAT pathway is utilized by
cytokines including interleukins (ILs), interferons (IFNs), and other molecules to transmit
signals from the cell membrane to the nucleus. Growing evidence suggests that JAK inhibitors
are efficacious in atopic dermatitis, alopecia areata, psoriasis and vitiligo.
It is a well known fact that the JAK-STAT pathway plays a pivotal role in the pathogenesis of
alopecia areata. Both phosphorylated STAT 1 and 3 have been found to be upregulated in the
disease. However, whether this pathway plays a role in other hair loss disorders remains
unclear. A study showedthat topical treatment of mouse and human skin with small molecule
inhibitors of the JAK-STATpathway resulted in rapid onset of anagen and subsequent hair
growth. It was shown that JAK inhibition regulates the activation of key hair follicle
populations such as the hair germ. These findings indicate that the JAK-STAT pathway may be
involved, not only in immune-mediated hair loss (alopecia areata), but also in the normal
hair cycle.
This current study aims at assessing STAT3 levels in patients with androgenetic alopecia, in
an attempt to detect a possible role of the JAK-STAT pathway in the pathogenesis of the
disease.
Objective:
The objective is to compare tissue levels of STAT3 in androgen-dependant areas in male
androgenetic alopecia patients with their level in non-involved, non-androgen dependant areas
(occipital scalp) in the same subjects.
Population of study & disease condition (e.g women with hepatitis, ............) Males with
androgenetic alopecia
Background and demographic characteristics( e.g age,.......)
- Age above 18 years.
- Males
Interventions :
Each subject will be subjected to:
- Informed consent.
- Detailed history and clinical evaluation to determine severity of disease.
- Punch biopsies (1mm) of affected area of scalp (androgen dependent area) from 25
patients with androgenetic alopecia.
- Punch biopsies(1mm) of normal area of scalp from occipital scalp (non-androgen dependent
area) from the same 25 patients
- Quantification of STAT3 by polymerase chain reaction (PCR).
Sample size (number of participants included)
- 25 participants (That will serve as both patients and controls)
- Sample size calculation was done using G ⃰ Power 3.1.9.2.
Possible. Risk Bleeding, secondary infection, scarring.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02591355 -
Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment
|
N/A | |
Withdrawn |
NCT03852992 -
Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
|
Phase 2 | |
Recruiting |
NCT06239207 -
Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia
|
Phase 2 | |
Completed |
NCT04945226 -
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
|
Phase 1/Phase 2 | |
Completed |
NCT01437163 -
Treatment of Androgenetic Alopecia in Males and Females
|
N/A | |
Completed |
NCT01548066 -
The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss
|
Phase 2 | |
Completed |
NCT01226459 -
Clinical Trial in Females for Female Pattern Hair Loss
|
Phase 3 | |
Recruiting |
NCT06118866 -
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
|
Phase 2 | |
Completed |
NCT06149221 -
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
|
N/A | |
Withdrawn |
NCT04882969 -
Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia
|
N/A | |
Completed |
NCT01231607 -
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
|
Phase 3 | |
Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
Completed |
NCT02729415 -
Point-of-Care Adipose-derived Cells for Hair Growth
|
N/A | |
Completed |
NCT02279823 -
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
|
Phase 2 | |
Not yet recruiting |
NCT01227031 -
Pharmacogenomic Study of Androgenetic Alopecia
|
N/A | |
Completed |
NCT00981461 -
Treatment of Androgenetic Alopecia in Females, 9 Beam
|
N/A | |
Completed |
NCT01451021 -
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss
|
Phase 2 | |
Completed |
NCT00151515 -
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
|
Phase 3 | |
Completed |
NCT03689452 -
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
|
N/A | |
Completed |
NCT03753113 -
Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%
|
Phase 3 |